Where to next for the A2 Milk (ASX:A2M) share price?

Is there any value left in the A2 Milk Company Ltd (ASX: A2M0 share price after it has been freefalling for the last 9 months? Here's what one broker thinks.

| More on:
pouring glass of milk from glass milk bottle

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It seems like the A2 Milk Company Ltd (ASX: A2M) share price has been left out to spoil. The last 9 months have been devastating for the company, as pantry destocking and weak China-related sales have seen its growth turn backwards. The A2 Milk share price has followed suit, falling close to 50% across the same period.

Here's a look at A2's recent half-year results, and what broker Bell Potter thinks could be in store for the company's share price.

A2 Milk's recent performance

A2 Milk's half-year results weren't pretty. The company's growth metrics across the board went backwards in an alarming double-digit fashion. Revenue, operating earnings before interest, taxes, depreciation, and amortisation (EBITDA) and operating net profit after tax were all down a respective 16%, 33%, and 36%. 

The company's lease-adjusted operating cash outflow came in at NZ$10.8 million, compared to the $159.9 million inflow in 1H20. This marks the company's first negative operating cash flow since 1H16. 

There were some small positives throughout the half-year results. This included strong growth within its liquid milk segment, growing 16.3% to $86.9 million with a record Australian market share of 11.7%. Liquid milk now represents 18% of the company's earnings, compared to 13% in the half ending June 2020. 

Elsewhere, the company lifted its Mother & Baby Store distribution points in China to 22,000 from 19,100 at FY20. Its rising footprint in China has translated to $213.1 million in sales, up 45.2%. 

The US remains a focal point for A2, with distribution points expanded to 22,200 points from 20,300 at FY20. 

Despite the small wins, the company's infant nutrition channels drive a majority of its earnings growth, which slumped from $765.7 million in 2H20 to $526.1 million in 1H21.

Looking ahead, FY21 revenue was forecast to be approximately NZ$1.4 billion with an EBITDA margin of 24–26%, implying EBITDA of NZ$336 million to $364 million. This guidance was also heavily caveated as relying on a material recovery in the last quarter of FY21. 

Bell Potter's A2 Milk share price target 

Bell Potter updated its A2 Milk share price target on 25 February to $8.65, which represents a downside of 3% to its share price at the time of writing.

Into this share price target, the broker incorporated A2's holding of Synlait Milk Ltd (ASX: SM1), a value for the expected upside in China based on projected stockists and sell-through rates, and a value for the US opportunity.

The broker commented that "A2 Milk is by no means cheap, neither is the sector and to a degree the material under performance of A2 Milk reflects this." 

Motley Fool contributor Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended A2 Milk. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A man in a suit smiles at the yellow piggy bank he holds in his hand.
Share Market News

Forget Westpac shares, these ASX ETFs could be better buys

Here's why these funds could be quality picks for investors looking for alternatives to the banks.

Read more »

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another tough day for investors.

Read more »

Rising real estate share price.
REITs

Macquarie names its top 4 ASX REITs to buy today

Macquarie expects these four dividend paying ASX REITs will all surge higher in 2026.

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Opinions

Forget CSL shares, I'd buy this booming biotech stock instead

This ASX biotech stock has caught my eye this year.

Read more »

Man with virtual white circles on his eye and AI written on top, symbolising artificial intelligence.
Broker Notes

Why this ASX AI stock could return 40% in 2026

Let's see which stock Bell Potter is tipping to rise strongly.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?

The biopharmaceutical company's shares are tipped to soar next year.

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Share Market News

Analysts name 2 top ASX 200 shares to buy today

Leading investment experts name two quality ASX 200 shares to buy now.

Read more »

Woman leaping in the air and standing out from her friends who are watching.
Broker Notes

This ASX 200 gold stock has surged 77% in 2025. Here's why Macquarie expects it to leap another 23%

Macquarie forecasts 23% upside for this surging ASX gold stock, and that doesn’t include the dividends!

Read more »